Medicortex USA Ltd Information

Medicortex USA Ltd. is a start-up pharmaceutical company focused on the discovery and pre-clinical development of innovative therapies for the treatment of acute neurodegenerative conditions, including Traumatic Brain Injury, exposure to toxic nerve agent and stroke. Medicortex's mission is to develop a truly effective neuroprotection therapy that limits the damage in brain injury, based on a novel multifunctional drug approach. By doing so, Medicortex will provide a solution to an unmet need for the treatment of acute neurodegenerative diseases. Currently, Medicortex operates in the United States and Israel. Medicortex will set-up three departments, including: Chemistry, In vitro and In vivo departments. The chemistry department will focus on the research of the molecular synthesis. The in vitro department will perform validation and proof of concept tests on neuronal tissue cultures, and the in vivo department will conduct animal model toxicology and efficacy research. The site in Israel is responsible for the development and management of the pre-clinical research program.